Mannose enhances anti-PD-1 therapy efficacy in ovarian cancer via modulating gut microbial metabolite.
RNA-seq (gene expression) · mouse · 16 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 16 samples: 5 × Tumor tissues, Control, vs 5 × Tumor tissues, Mannose, vs 3 × CD8TILs, Control, vs 3 × CD8TILs, Mannose,Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE271477_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1131788 and SRA study SRP517978. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 5 samples read as cases, 3 as controls.
How we read this: 4 replicated groups read from 16 sample titles; they account for 16 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8377739 Tumor tissues, Control, rep 1 Tumor tissues, Control,
- GSM8377740 Tumor tissues, Control, rep 2 Tumor tissues, Control,
- GSM8377741 Tumor tissues, Control, rep 3 Tumor tissues, Control,
- GSM8377742 Tumor tissues, Control, rep 4 Tumor tissues, Control,
- GSM8377743 Tumor tissues, Control, rep 5 Tumor tissues, Control,
- GSM8377744 Tumor tissues, Mannose, rep 1 Tumor tissues, Mannose,
- GSM8377745 Tumor tissues, Mannose, rep 2 Tumor tissues, Mannose,
- GSM8377746 Tumor tissues, Mannose, rep 3 Tumor tissues, Mannose,
- GSM8377747 Tumor tissues, Mannose, rep 4 Tumor tissues, Mannose,
- GSM8377748 Tumor tissues, Mannose, rep 5 Tumor tissues, Mannose,
- GSM8377749 CD8TILs, Control, rep 1 CD8TILs, Control,
- GSM8377750 CD8TILs, Control, rep 2 CD8TILs, Control,
- GSM8377751 CD8TILs, Control, rep 3 CD8TILs, Control,
- GSM8377752 CD8TILs, Mannose, rep 1 CD8TILs, Mannose,
- GSM8377753 CD8TILs, Mannose, rep 2 CD8TILs, Mannose,
- GSM8377754 CD8TILs, Mannose, rep 3 CD8TILs, Mannose,
- GSE285965 Mannose enhances anti-PD-1 therapy efficacy in ovarian cancer via modulating gut microbial metabolite [Peritoneum] 24 samples shares anti-pd-1, modulating, metabolite, microbial, enhances, efficacy, mannose, therapy
- GSE334585 iNOS is a key mediator of anti-PD-1 melanoma therapy response 48 samples shares anti-pd-1, therapy
- GSE263274 Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies 45 samples shares anti-pd-1, therapy
- GSE266110 7aaRGD - a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas 40 samples shares anti-pd-1, therapy
- GSE292614 Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy [scRNAseq] 24 samples shares anti-pd-1, therapy
- GSE282979 IL-2/IL-15 signaling induces NK cell production of FLT3LG which augments anti-PD-1 immunotherapy 24 samples shares anti-pd-1, therapy
- GSE314594 Cryo-thermal therapy reprograms myeloid cells into CCL5+ mature phenotype to increase T cell infiltration and potentiates anti-PD-1 therapy 18 samples shares anti-pd-1, therapy
- GSE263240 Blocking CX3CR1+ Tumor-associated Macrophages Synergize with anti-PD-1 Therapy in Hepatocellular Carcinoma 16 samples shares anti-pd-1, therapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.